[{"from": "human", "value": "Describe this molecule. [C][O][C][C][C][N][C][C][C][Branch1][Branch1][C][C][Ring1][=Branch1][N][C][=Branch1][C][=O][C][=C][C][=Branch1][=C][=C][Branch1][#Branch2][C][=C][Ring1][=Branch1][O][C][C][Ring1][Branch1][N][Cl]"}, {"from": "gpt", "value": "The molecule is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018."}]